(CE) Celanese - Overview
Stock: Acetyls, Engineered Polymers, Thermoplastics, Resins, Elastomers
| Risk 5d forecast | |
|---|---|
| Volatility | 54.8% |
| Relative Tail Risk | -9.70% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.29 |
| Alpha | -23.30 |
| Character TTM | |
|---|---|
| Beta | 1.853 |
| Beta Downside | 2.336 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.96% |
| CAGR/Max DD | -0.28 |
EPS (Earnings per Share)
Revenue
Description: CE Celanese January 09, 2026
Celanese Corporation (NYSE:CE) is a global chemical and specialty-materials producer that operates two primary segments. The Engineered Materials segment supplies a broad portfolio of high-performance polymers-including nylon, polypropylene, polyoxymethylene, liquid-crystal polymers, and thermoplastic elastomers-for end-markets such as automotive, medical devices, consumer electronics, and energy-storage systems. The Acetyl Chain segment manufactures acetyl-based intermediates (e.g., acetic acid, vinyl acetate monomer, ethylene-vinyl acetate resins) used in paints, coatings, adhesives, flexible packaging, and pharmaceutical applications. Products are sold under well-known brands like Zytel, Hytrel, and Santoprene, primarily through direct OEM relationships and a network of distributors.
Key operating metrics that analysts watch include • 2023 revenue of roughly $9.1 billion, with the Engineered Materials segment contributing about 55 % of total sales; • adjusted EBITDA margin hovering near 13 %-a level that reflects both pricing power in specialty polymers and exposure to volatile natural-gas feedstock costs; • capacity utilization rates of ~ 85 % across its U.S. and European plants, which can be a leading indicator of demand trends in automotive lightweighting and battery-case production. Macro-level drivers for Celanese are the global shift toward electrification (boosting demand for high-temperature polymers), cyclical construction activity (affecting polyphenylene sulfide and PVC-based products), and the price trajectory of natural gas, which accounts for roughly 30 % of its variable production costs.
For a deeper, data-driven view of Celanese’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -1.72b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 0.86 > 1.0 |
| NWC/Revenue: 21.17% < 20% (prev 14.76%; Δ 6.41% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.19b > Net Income -1.72b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (109.8m) vs 12m ago 0.24% < -2% |
| Gross Margin: 20.78% > 18% (prev 0.23%; Δ 2055 % > 0.5%) |
| Asset Turnover: 39.91% > 50% (prev 40.47%; Δ -0.57% > 0%) |
| Interest Coverage Ratio: -5.64 > 6 (EBITDA TTM -210.0m / Interest Expense TTM 365.0m) |
Altman Z'' 2.07
| A: 0.09 (Total Current Assets 5.69b - Total Current Liabilities 3.68b) / Total Assets 21.70b |
| B: 0.46 (Retained Earnings 9.88b / Total Assets 21.70b) |
| C: -0.09 (EBIT TTM -2.06b / Avg Total Assets 23.79b) |
| D: 0.53 (Book Value of Equity 9.10b / Total Liabilities 17.22b) |
| Altman-Z'' Score: 2.07 = BBB |
Beneish M -3.61
| DSRI: 0.50 (Receivables 922.0m/2.06b, Revenue 9.49b/10.48b) |
| GMI: 1.12 (GM 20.78% / 23.19%) |
| AQI: 0.88 (AQ_t 0.49 / AQ_t-1 0.55) |
| SGI: 0.91 (Revenue 9.49b / 10.48b) |
| TATA: -0.13 (NI -1.72b - CFO 1.19b) / TA 21.70b) |
| Beneish M-Score: -3.61 (Cap -4..+1) = AAA |
What is the price of CE shares?
Over the past week, the price has changed by -8.05%, over one month by +22.34%, over three months by +52.29% and over the past year by +3.10%.
Is CE a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 12
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.7 | 1.1% |
| Analysts Target Price | 54.7 | 1.1% |
CE Fundamental Data Overview February 19, 2026
P/S = 0.6286
P/B = 1.6298
P/EG = 4.4198
Revenue TTM = 9.49b USD
EBIT TTM = -2.06b USD
EBITDA TTM = -210.0m USD
Long Term Debt = 11.65b USD (from longTermDebt, last quarter)
Short Term Debt = 1.20b USD (from shortTermDebt, last quarter)
Debt = 1.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 206.0m USD (from netDebt column, last quarter)
Enterprise Value = 6.13b USD (6.10b + Debt 1.47b - CCE 1.44b)
Interest Coverage Ratio = -5.64 (Ebit TTM -2.06b / Interest Expense TTM 365.0m)
EV/FCF = 6.87x (Enterprise Value 6.13b / FCF TTM 893.0m)
FCF Yield = 14.56% (FCF TTM 893.0m / Enterprise Value 6.13b)
FCF Margin = 9.40% (FCF TTM 893.0m / Revenue TTM 9.49b)
Net Margin = -18.14% (Net Income TTM -1.72b / Revenue TTM 9.49b)
Gross Margin = 20.78% ((Revenue TTM 9.49b - Cost of Revenue TTM 7.52b) / Revenue TTM)
Gross Margin QoQ = 19.19% (prev 21.13%)
Tobins Q-Ratio = 0.28 (Enterprise Value 6.13b / Total Assets 21.70b)
Interest Expense / Debt = -12.05% (Interest Expense -177.0m / Debt 1.47b)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.63b (EBIT -2.06b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.55 (Total Current Assets 5.69b / Total Current Liabilities 3.68b)
Debt / Equity = 0.36 (Debt 1.47b / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = -0.98 (negative EBITDA) (Net Debt 206.0m / EBITDA -210.0m)
Debt / FCF = 0.23 (Net Debt 206.0m / FCF TTM 893.0m)
Total Stockholder Equity = 4.92b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.24% (Net Income -1.72b / Total Assets 21.70b)
RoE = -34.99% (Net Income TTM -1.72b / Total Stockholder Equity 4.92b)
RoCE = -12.42% (EBIT -2.06b / Capital Employed (Equity 4.92b + L.T.Debt 11.65b))
RoIC = -9.20% (negative operating profit) (NOPAT -1.63b / Invested Capital 17.69b)
WACC = 10.27% (E(6.10b)/V(7.57b) * Re(12.74%) + (debt cost/tax rate unavailable))
Discount Rate = 12.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.14%
[DCF Debug] Terminal Value 66.42% ; FCFF base≈873.4m ; Y1≈723.5m ; Y5≈525.6m
Fair Price DCF = 60.01 (EV 6.78b - Net Debt 206.0m = Equity 6.57b / Shares 109.5m; r=10.27% [WACC]; 5y FCF grow -20.68% → 2.90% )
EPS Correlation: -80.35 | EPS CAGR: -58.50% | SUE: -3.85 | # QB: 0
Revenue Correlation: -22.13 | Revenue CAGR: -3.95% | SUE: -0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.92 | Chg30d=-0.029 | Revisions Net=-4 | Analysts=10
EPS next Year (2026-12-31): EPS=5.44 | Chg30d=-0.118 | Revisions Net=-5 | Growth EPS=+27.9% | Growth Revenue=-0.1%